The management of Paget's disease of bone

New England Journal of Medicine

Volumn 336, Issue 8, 1997, Pages 558-566

  Delmas, Pierre D ^a   Meunier, Pierre J ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITONIN RECEPTOR; CLODRONIC ACID; ETIDRONIC ACID; GALLIUM NITRATE; IBANDRONIC ACID; MITHRAMYCIN; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

BONE MARROW TOXICITY; BONE MINERALIZATION; BONE PAIN; CLINICAL FEATURE; DRUG EFFECT; DRUG INDICATION; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HUMAN; INFLUENZA; LIVER TOXICITY; NEPHROTOXICITY; PAGET BONE DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

DIPHOSPHONATES; HUMANS; OSTEITIS DEFORMANS;

EID: 0031059787     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199702203360807     Document Type: Review

References (71)

1. Meunier PJ, Coindre J, Edouard CM, Arlot ME. Bone histomorphometry in Paget's disease: quantitative and dynamic analysis of pagetic and nonpagetic bone tissue. Arthritis Rheum 1980;23:1095-103.
2. Kanis JA. Pathophysiology and treatment of Paget's disease of bone. London: Martin Dunitz, 1991.
3. Meunier PJ, Saison C, Mathieu L, et al. Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop 1987;217:37-44.
4. Vellenga CJLR, Pauwels EKJ, Bijvoet OLM, Frijlink WB, Mulder JD, Hermans J. Untreated Paget's disease of bone studied by scintigraphy. Radiology 1984;153:799-805.
5. Siris ES. Paget's disease of bone. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 2nd ed. New York: Raven Press, 1993:375-84.
6. Rebel A, Malkani K, Basle M. Anomalies nucléaires des ostéoclastes de la maladie osseuse de Paget. Nouv Presse Med 1974;3:1299-301.
7. Bone HG, Kleerekoper M. Paget's disease of bone. J Clin Endocrinol Metab 1992;75:1179-82.
8. Mills BG, Frausto A, Singer FR, et al. Multinucleated cells formed in vitro from Paget's bone marrow express viral antigens. Bone 1994;15:443-8.
9. Walton RJ, Preston CJ, Bartlett M, Smith R, Russell RG. Biochemical measurements in Paget's disease of bone. Eur J Clin Invest 1977;7:37-9.
10. Alvarez L, Guanabens N, Peris P, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 1995;10:458-65.
11. Delmas PD, Demiaux B, Malaval L, Chapuy MC, Meunier PJ. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif Tissue Int 1986;38:60-1.
12. Uebelhart D, Gineyts E, Chapuy MCC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.
13. Altman RD. Paget's disease of bone. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992: 1027-64.
14. Gonzalez D, Vega E, Ghiringhelli G, Mautalen C. Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin in Paget's disease. Calcif Tissue Int 1987;41:313-5.
15. Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT Jr, Bloch KJ. An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 1972;51:2331-8.
16. Haddad JG Jr, Caldwell JG. Calcitonin resistance: clinical and immunologic studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonin. J Clin Invest 1972;51:3133-41.
17. Dietrich FM, Fischer JA, Bijvoet OLM. Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease. Acta Endocrinol 1979;92:468-76.
18. Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget's disease of bone: the problem of acquired clinical resistance. Arthritis Rheum 1980;23:1148-54.
19. Ziegler R, Minne H, Holz G, Delling G. Secondary hyperparathyroidism due to calcitonin treatment in Paget's disease of bone. In: Copp DH, Talmage RV, eds. Endocrinology of calcium metabolism. Amsterdam: Excerpta Medica, 1978:406. abstract.
20. Solomon LR, Evanson JM, Canty DP, Gill NW. Effects of calcitonin treatment on deafness due to Paget's disease of bone. BMJ 1977;2:485-7.
21. el Sammaa M, Linthicum FH Jr, House HP, House JW. Calcitonin as treatment for hearing loss in Paget's disease. Am J Otol 1986;7:241-3.
22. Melick RA, Ebeling P, Hjorth RJ. Improvement in paraplegia in vertebral Paget's disease treated with calcitonin. BMJ 1976;1:627-8.
23. Ryan WG, Schwartz TB. Mithramycin treatment of Paget's disease of bone: exploration of combined mithramycin-EHDP therapy. Arthritis Rheum 1980;23:1155-61.
24. Matkovic V, Apseloff G, Shepard DR, Gerber N. Use of gallium to treat Paget's disease of bone: a pilot study. Lancet 1990;335:72-5.
25. Fleisch H. Bisphosphonate in bone disease: from the laboratory to the patient. 2nd ed. Carnforth, England: Parthenon Publishing, 1995.
26. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture in vivo. Science 1969;165:1262-4.
27. Zimolo Z, Wesolowski G, Rodan GA. Acid extrusion is induced by osteoclast attachment to bone: inhibition by alendronate and calcitonin. J Clin Invest 1995;96:2277-83.
28. Fleisch H. Bisphosphonates: mechanisms of action and clinical use. In: Mundy GR, Martin TJ, eds. 1993 Physiology and pharmacology of bone. Handbook of experimental pharmacology. Vol. 107. Berlin, Germany: Springer-Verlag, 1993:377-418.
29. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-11.
30. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ. Bisphosphonates: structure-activity relationships and therapeutic implications. In: Heersche JNM, Kanis JA, eds. 1994 Bone and mineral research. Amsterdam: Elsevier, 1994:265-306.
31. Terreaux F, Delmas PD, Chapuy MC, et al. Treatment of Paget's disease with oral alendronate. J Bone Miner Res 1994;9:Suppl 1:S291. abstract.
32. Charhon S, Chapuy MC, Valentin-Opran A, Meunier PJ. Intravenous etidronate for spinal cord dysfunction due to Paget's disease. Lancet 1982; 1:391-2.
33. Meunier PJ, Ravault A. Treatment of Paget's disease with etidronate disodium. In: Singer FR, Wallach S, eds. Paget's disease of bone: clinical assessment, present and future therapy. New York: Elsevier, 1991:86-99.
34. Altman RD, Johnston CC, Khairi MRA, Wellman H, Serafini AN, Sankey RR. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 1973;289:1379-84.
35. Siris ES, Canfield RE, Jacobs TP, Stoddart KE, Spector PJ. Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy. Metab Bone Dis Relat Res 1981;3:301-8.
36. Altman RD, Collins B. Disodium etidronate (EHDP) in Paget's disease (Pag D): 11 year study of 93 patients. Arthritis Rheum 1983;26: Suppl:S9. abstract.
37. Alexandre CM, Chapuy MC, Vignon E, Edouard C, Johnston CC, Meunier PJ. Treatment of Paget's disease of bone with ethane-1 hydroxy-1,1 diphosphonate (EHDP) at a low dosage (5 mg/kg/day). Clin Orthop 1983;174:193-205.
38. Johnston CC Jr, Altman RD, Canfield RE, Finerman GA, Taulbee JD, Ebert ML. Review of fracture experience during treatment of Paget's disease of bone with etidronate disodium (EHDP). Clin Orthop 1983;172: 186-94.
39. Frijlink WB, Bijvoet OLM, te Velde J, Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet 1979;1:799-803.
40. Bijvoet OLM, Frijlink WB, Jie K, et al. APD in Paget's disease of bone: role of the mononuclear phagocyte system? Arthritis Rheum 1980;23: 1193-204.
41. Mautalen CA, Gonzalez D, Ghiringhelli G. Efficacy of the bisphosphonate APD in the control of Paget's bone disease. Bone 1985;6:429-32.
42. Thiebaud D, Jaeger P, Burckhardt P. Paget's disease of bone treated in five days with AHPrBP (APD) per Os. J Bone Miner Res 1987;2:45-52.
43. Heynen G, Delwaide P, Bijvoet OLM, Franchimont P. Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone. Eur J Clin Invest 1982;12: 29-35.
44. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320-2.
45. Cantrill JA, Buckler HM, Anderson DC. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone. Ann Rheum Dis 1986;45:1012-8.
46. Vega E, Gonzalez D, Ghiringhelli G, Mautalen C. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease. J Bone Miner Res 1987;2:267-71.
47. Thiebaud D, Jaeger P, Gobelet C, Jacquet AF, Burckhardt P. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med 1988;85:207-12.
48. Delmas PD, Casez JP, Arlot MA, Chapuy MC, et al. Long term effects of intravenous (IV) aminopropylidene diphosphonate (APD) in patients with refractory Paget's disease of bone. Calcif Tissue Int 1989;44:Suppl: S104. abstract.
49. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF. Mineralisation detects with pamidronate therapy for Paget's disease. Lancet 1993;342:1459-60.
50. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994;343:953-4.
51. Adami S, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 1994;15:415-7.
52. Meunier PJ, Chapuy MC, Alexandre C, et al. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet 1979; 2:489-92.
53. Douglas DL, Duckworth T, Kanis JA, et al. Biochemical and clinical responses to dichloromethylene diphosphonate (C12MDP) in Paget's disease of hone. Arthritis Rheum 1980;23:1185-92.
54. Delmas PD, Chapuy MC, Vignon E, et al. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab 1982;54:837-44.
55. Yates AJP, Percival RC, Gray RES, et al. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet 1985;1:1474-7.
56. McClung MR, Tou CK, Goldstein NH, Picot C. Tiludronate therapy for Paget's disease of bone. Bone 1995;17:Suppl:493S-496S.
57. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 1995;38:851-8.
58. Delmas PD, Chapuy M-C, Edouard C, Meunier PJ. Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am J Med 1987;83:276-82.
59. Atkins RM, Yates AJP, Gray RES, et al. Aminohexane diphosphonate in the treatment of Paget's disease of bone. J Bone Miner Res 1987;2:273-9.
60. Schweitzer DH, Zwinderman AH, Vermeij P, Bijvoet OL, Papapoulos SE. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1993;8:175-82.
61. Chines A, Bekker P, Clarke P, Hosking D. Reduction of bone pain and alkaline phosphatase in patients with severe Paget's disease of bone following treatment with risedronate. J Bone Miner Res 1996;11:Suppl 1:5371. abstract.
62. Zelenakas K, Buckler H, Ryan W, Schaffer V, Richardson P. A double-blind placebo-controlled trial using intravenous CGP-42446 in patients with Paget's disease of bone. Bone 1995;17:618. abstract.
63. Knaus J, Grauer A, Seibel MJ, Ziegler R. Treatment of Paget's disease of bone with the new bisphosphonate ibandronate (BM 21.0955) by intravenous injection and continuous infusion. Bone 1995;17:614. abstract.
64. Meunier PJ, Vignot E. Therapeutic strategy in Paget's disease of bone. Bone 1995;17:Suppl:489S-491S.
65. Gray RE, Yates AJ, Preston CJ, Smith R, Russell RG, Kanis JA. Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med 1987;64:755-67.
66. Harinck HI, Bijvoet OL, Blanksma HJ, Dahlinghaus-Nienhuys PJ. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop 1987;217:79-98.
67. Altman RD. Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone. Am J Med 1985;79:583-90.
68. Mautalen CA, Gonzalez D, Ghiringhelli G. Efficacy of the bisphosphonate APD in the control of Paget's bone disease. Bone 1985;6:429-32.
69. Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget's disease of bone. J Bone Miner Res 1993;8:1467-73.
70. Woodhouse NJY, Chalmers AH, Wells IP, Dewbury KC, Mohamedally SM. Paget's disease: radiological changes occurring in untreated patients and those on therapy with salmon calcitonin during two years' observation. Br J Radiol 1977;50:699-705.
71. Kanis JA, Gray RES. Long-term follow-up observations on treatment in Paget's disease of bone. Clin Orthop 1987;217:99-125.